By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN


Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display

Company News
Amgen (AMGN) Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine 6/19/2015 2:38:55 PM
Amgen (AMGN) Release: Results From Phase III Trial Show Vectibix (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care 6/19/2015 7:52:37 AM
Amgen (AMGN) Brings in More Good News on Phase III Cancer Trial 6/19/2015 6:00:07 AM
Open Monoclonal Technology, Inc. Announces OmniAb Alliance With Amgen (AMGN) 6/15/2015 10:58:39 AM
Why Is Amgen (AMGN) Rising And Regeneron (REGN) Falling? 6/12/2015 6:51:47 AM
Amgen (AMGN)'s Repatha Decision Not Unexpected But Caveats Are Key, Say Analysts 6/11/2015 9:37:15 AM
FDA Panel Backs Amgen (AMGN)'s Repatha, But With Strings Attached 6/11/2015 6:04:30 AM
Amgen (AMGN) To Discuss Details Of Repatha (Evolocumab) Biologics License Application For The Treatment Of High Cholesterol 6/10/2015 6:59:45 AM
Amgen (AMGN) To Present At The Goldman, Sachs & Co. Global Healthcare Conference 6/9/2015 7:55:22 AM
Allied Minds Names Kevin Sharer, Former Chairman And CEO Of Amgen (AMGN), To Board Of Directors 6/5/2015 7:48:58 AM